Approval needs an approval record
US approval records held no cagrilintide or CagriSema product at the September 28, 2026 check.
The US drug regulator is the Food and Drug Administration (FDA).
- A drug-directory code does not prove approval. FDA cautioned about this at the September 26, 2026 check.
- Record the exact ingredient and product name. Note the form too: a shot or a tablet.
- Keep the date you read the record beside the answer.
For a study, ask for its code
A study’s NCT code lets you find its record on ClinicalTrials.gov, the public US study register.
- A matching registered study does not prove an offer is connected to it.
- Find the research team’s contact details in the public study record, rather than using only the details in the offer.
- Ask that team to confirm that the invitation comes from them before deciding whether to take part.
The date is part of the answer
CagriSema was still under FDA review on September 28, 2026. The developer expected a decision in late 2026.
- An expected decision is not the same as approval.
- If a new announcement appears, check the exact product and what the decision covers.
- Write down what is still missing and ask the care professional or research team who can check it.
Finish with a care question you can answer
Bring the notes back to a care discussion.
- Is there an approved product for this exact offer?
- Who will assess the health question?
- Which state licence or permission covers the visit?
- Who sends any medicine, and what does the full care cost?
